

# Nectar Lifesciences Ltd.



Ref.: NLL/CS/2025- 450

January 08, 2025

**To**

1. National Stock Exchange of India Limited  
Listing Department,  
Exchange Plaza, Bandra Kurla Complex,  
Bandra (E), Mumbai 400 051

**Symbol: NECLIFE**

2. BSE Limited  
Corporate Relationship Department,  
P J Towers, Dalal Street,  
Mumbai 400 001

**Scrip Code: 532649**

**Sub: Voluntary Intimation of Schedule of Analyst / Institutional Investor Meetings (One to One Meet)**

**Ref: Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements), Regulations 2015.**

Dear Sir/ Madam,

Pursuant to captioned regulations, we would like to inform you that the officials of the Company will be meeting Investors (Participants) as per details below:

<b>Date</b>	<b>Type of Interaction</b>	<b>Place of Meet</b>
Thursday/ Friday, January 09/ 10, 2025	One to One Meet (In-person Meetings)	Mumbai

The presentation proposed to be presented in the meet is attached herewith and is also available on the website of the Company.

The Company will be referring to publicly available documents for discussions during interaction in the One-to-One meet and no unpublished price sensitive information is proposed to be shared during the meeting.

Kindly note that changes may happen due to exigencies on the part of Participants/ Company.

Kindly take the same on record and oblige.

Thanking you,

Yours faithfully,

For **Nectar Lifesciences Limited**

(Neha Vaishnav)


**Company Secretary & Compliance Officer**



**Nectar Lifesciences Ltd.**

**November 2024**


# DISCLAIMER




In this presentation, we have disclosed forward- looking information.. This presentation is based on certain forward looking statements that we periodically make to anticipate results based on the management's plans and assumptions. We have tried wherever possible to identify such statements by using words such as 'anticipates', 'estimates', 'projects', 'intends', 'plans', 'believes', and words of similar substance in connection with any discussion of future performance. We cannot guarantee that these forward looking statements will be realized, although we believe we have prudent in assumptions. This achievement of results is subject to risks, uncertainties, and even inaccurate assumptions. Should know or unknown risks or uncertainties materialize, or should underlying assumptions prove inaccurate, actual results could vary materially from those anticipated, or estimated projected. We undertake no obligation to publicity update any forward looking statements, whether as a results of new information, future events or otherwise.

# ABOUT THE COMPANY- NECTAR LIFESCIENCES LTD






# Geography & Locations



Landmark	Location	Activity
Corporate HQ	Chandigarh	Corporate Functions Global <ul style="list-style-type: none"><li>• Marketing &amp; BD</li><li>• Finance &amp; Accounting</li><li>• Supply chain</li><li>• Secretarial &amp; Legal</li></ul>
API Manufacturing Unit I	Derabassi, Punjab	<i>Oral &amp; Sterile APIs</i>
API Manufacturing Unit II	Derabassi, Punjab	<i>Oral &amp; Sterile APIs</i>
Formulation Manufacturing Unit	Barotiwala Himachal Pradesh	<i>FDFs</i> <i>- Oral &amp; Injectables</i>
Capsule Manufacturing Unit	Barotiwala Himachal Pradesh	<i>Empty Hard Gelatin Capsule Manufacturing</i>



# LANDMARK TIMELINE



# OUR STRENGTHS

**Well equipped to scale and capture large market share**

**Leading manufacturers of Cephalosporin API Products**

**44 DMF's filed, 9 CEP's & 4 MAP's approved, 15 ANDA filings**

- **120 + Acre API campus.**
- **One of the leading manufacturers in the World.**
- **State of the art facilities .**

**Competitive Advantages and High Barriers to entry**

**Established Relationships with Marquee Customers**



**Transformation:** Evolved from a small domestic API player to a major global player in the Cephalosporins industry.

**Global Reach:** Strong presence in API and formulation business in nearly 45 countries.

**Manufacturing Facilities:** Operates state-of-the-art manufacturing plants in Punjab and Himachal Pradesh. One of the leading Indian manufacturers in the API sector.

**Regulatory Compliance:** Adheres to global standards of cGMP and Environment Health Safety (EHS).

**Workforce:** Employees thousands of highly skilled and qualified professionals across various levels.

**Public Listing:** Company is publicly listed with stocks traded on BSE and NSE.

# R&D INFRASTRUCTURE

## PROCESSES


- Sterile Crystallization & Lyophilization
- Asymmetric Synthesis
- Chemical Resolution
- Enzymatic Catalysis
- Amino acids

- LCMS/MS
- Ion Chromatography
- Preparative HPLC
- Freeze Dryers
- HPLC
- Gas chromatography
- UV photometer
- Infrared spectroscopy

## ANALYTICAL R&D



# Global Cephalosporins Drug Market 2020-30



The global cephalosporin drugs market size was valued at USD 19.38 billion in 2023 and is growing at a rapid rate.

# Cephalosporin Global Landscape

World Pharmaceutical Market: \$1.2tn

Antibiotics Market: \$100bn (Gen I-V)


Ceph Market: \$19bn (Gen I-V)

\$16bn

Addressable Market  
for the company

# Nectar Lifesciences API Leadership

## Oral Cephalosporin




- NLL has leading global capacities in Cefixime, Cefuroxime Axetil Amorphous, Cefuroxime Axetil Crystalline, Cefotaxime Sodium, and Ceftriaxone Sodium

## Sterile Cephalosporins



# Nectar Lifescience's Global Reach



## Latin America

Brazil Ecuador  
Cambodia Mexico  
Colombia Venezuela

## Europe

Belarus Russia  
Bulgaria Slovakia  
Hungary Spain  
Kazakhstan Turkey  
Romania Ukraine

## New Markets

Japan, Korea,  
China

## Africa & Middle-East

Algeria Morocco Syria  
Egypt Nigeria Tunisia  
Ethiopia Oman UAE  
Israel Sudan Yemen  
Saudi Arabia Jordan

## Asia Pacific

Afghanistan Nepal  
Bangladesh Pakistan  
Cambodia Philippines  
Myanmar



# API Manufacturing Unit 1





# API Manufacturing Unit 2





# API's and STERILE FACILITY


- This facility has:
  - *Reactors of varied construction features.*
  - *Together with matching capacities of centrifuges, driers and various other production equipment.*
  
- Spray drying facility for Cefuroxime Axetil Amorphous.



# API Unit Accreditations



# Nectar API Global Business Presence



# Formulation Unit Accreditations







# FORMULATION FACILITY



# Nectar FDF Global Business Presence



# Management Expertise and Bandwidth





# NLL - Self-Sufficient Organization



- **2\*6 MW capacity plant in API Unit-II Derabassi, Pb.**
- **Solvent reduction is the sweet spot for greening any pharma process.**
- 



- **We at NLL strongly believe in replacement of organic solvents with safer available aqueous solvents & similar other available options to protect the environment and health as well as industrial safety.**
- **NLL strongly believes in developing or improving existing chemical products and processes to make them less hazardous to human health and environment.**
- **After Years of efforts NLL now has an expertise in recovery as a whole.**



# Cephalosporins- Long Chain and Pipeline

## Generation 1-

Cefalexin, Cefadroxil, Cefazolin, Cefapirin, Cefacetrile, Cefaloglycin, Cefalonium, Cefaloridine, Cefalotin, Cefatrizine, Cefazaflur, Cefazedone, Cefradine, Cefroxadine, Ceftezole.

## Generation 2-

Cefuroxime, Cefprozil, Cefaclor, Cefonicid, Cefuzonam, Cefamandole, Cefoxitin, Cefotetan, Cefmetazole, Cefminox, Cefbuperazone, Cefotiam, Loracarbef

## Generation 3-

Cefdinir, Ceftriaxone, Ceftazidime, Cefixime, Cefpodoxime, Ceftiofur, Cefotaxime, Ceftizoxime, Cefditoren, Ceftributen, Cefovecin, Cefdaloxime, Cefcapene, Cefetamet, Cefmenoxime, Cefodizime, Cefpimizole, Cefteram, Ceftiolene, Cefoperazone

## Generation 4

Cefepime, Cefiderocol, Cefquinome, Cefclidine, Cefluprenam, Cefoselis, Cefozopran, Cefpirome

## Generation 5

Ceftaroline, Ceftolozane, Ceftobiprole, Cefaloram, Cefaparole, Cefcanel, Cefedrolor, Cefempidone, Cefetrizole, Cefivitril, Cefmatilen, Cefmepidium, Cefoxazole, Cefrotil, Cefsumide, Ceftioxide, Cefuracetime

# Competitive Advantage of Nectar

1

## Expertise and Experience

Nectar has over two decades of experience in the manufacturing and distribution of high-quality, cost-effective Cephalosporin and other antibiotics.

2

## Marketing and Distribution

Our extensive network of distribution channels, supply chain capabilities, and aggressive marketing strategy gives us a competitive edge in the Cephalosporin market.

3

## Innovative Products and Services

Nectar maintains a strong focus on research and development, which has led to the production of many innovative and cost-effective dosage forms, including extended-release formulations and injectables.


# FINANCIALS



# Income Statement & Financial Summary

INR Lacs

S. No.	Particulars	Quarter Ended			Half Year		Year Ended
		30-Sep-24	30-Jun-24	30-Sep-23	30-Sep-24	30-Sep-23	31-Mar-24
		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
I	<b>Income from Operations</b>						
	Sales	49,744.73	41,750.91	44,962.85	91,495.64	90,063.12	192,583.19
	Less: GST Recovered	6,956.27	5,866.21	5,167.14	12,822.48	10,855.78	24,174.62
	<b>Revenue from Operations</b>	<b>42,788.46</b>	<b>35,884.70</b>	<b>39,795.71</b>	<b>78,673.16</b>	<b>79,207.34</b>	<b>168,408.57</b>
	Other operating Income	21.33	45.27	0.62	66.60	1.25	154.56
II	Other Income	68.94	55.08	1,060.83	124.02	1,108.14	1,303.00
III	<b>Total Income (I + II)</b>	<b>42,878.73</b>	<b>35,985.05</b>	<b>40,857.16</b>	<b>78,863.78</b>	<b>80,316.73</b>	<b>169,866.13</b>
IV	<b>Expenses</b>						
	(a) Cost of Materials consumed	25,388.87	29,698.35	25,615.94	55,087.22	53,981.21	124,244.99
	(b) Purchase of Stock in Trade	-	-	-	-	-	-
	(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	4,215.53	(5,964.12)	3,162.78	(1,748.59)	2,714.26	(4,020.82)
	(d) Employee benefits expense	2,417.97	2,398.66	2,030.93	4,816.63	3,910.55	8,467.08
	(e) Finance costs	1,980.79	1,997.68	2,051.92	3,978.47	3,814.17	8,714.17
	(f) Depreciation and amortisation expense	1,554.87	1,546.03	1,531.23	3,100.90	3,064.48	6,071.84
	(g) Other expenses	6,454.09	5,816.74	6,300.21	12,270.83	12,362.07	24,561.98
	<b>Total Expenses (IV)</b>	<b>42,012.12</b>	<b>35,493.34</b>	<b>40,693.01</b>	<b>77,505.46</b>	<b>79,846.74</b>	<b>168,039.24</b>
V	<b>Profit before exceptional items and tax (III- IV)</b>	<b>866.61</b>	<b>491.71</b>	<b>164.15</b>	<b>1,358.32</b>	<b>469.99</b>	<b>1,826.89</b>
VII	<b>Profit from ordinary activities before tax (V - VI)</b>	<b>866.61</b>	<b>491.71</b>	<b>164.15</b>	<b>1,358.32</b>	<b>469.99</b>	<b>1,826.89</b>
VIII	<b>Tax Expense</b>						
	(1) Current Tax	-	-	-	-	-	-
	(2) Deferred Tax	306.72	194.80	62.62	501.52	186.42	1,327.43
IX	<b>Profit for the period from continuing operations (VII-VIII)</b>	<b>559.89</b>	<b>296.91</b>	<b>101.53</b>	<b>856.80</b>	<b>283.57</b>	<b>499.46</b>
	<b>Total Comprehensive Income for the period</b>	<b>559.89</b>	<b>296.91</b>	<b>101.53</b>	<b>856.80</b>	<b>283.57</b>	<b>465.33</b>
X	Earnings per Share (EPS) (Equity shares of Re. 1/- each fully paid up)	0.25	0.13	0.05	0.38	0.13	0.22



## **Established in 2010**

**Mission:** To elevate its status to a center of excellence in Women's technical education by a conscious and consistent enhancement of its performance.

### **Major Contributions**

- Providing free education to girls belonging to BPL families.
- Impart basic Computer and English education free of cost to each and every girl irrespective of their course. Providing Education in the villages. Helping the students in placements. Helping the students in opening their Boutiques and Parlors. Diploma in Fashion Technology. Diploma in Textile Designing. B.Sc. Fashion Technology. B.Sc. Textile Design



# AWARDS AND ACCOLADES



**Ranked 412 in Fortune India 500  
companies  
Year 2019**



**Outstanding Export Performance award in  
API by Pharmexcil  
Year 2019**



**Currently Ranked 419 Amongst Indian  
Companies by Economic Times  
Year 2019**



**National Energy Conservation Award  
(NECA)  
Year 2015**



**National Energy Conservation Award  
(NECA)  
Year 2018**

**THANK YOU**

